The Intensive Care Platform Trial INCEPT Evaluating Treatments for Adults in Intensive Care Units to Improve Outcomes

What this Trial Is About

Critically ill adults admitted to intensive care units ICUs often face high mortality and long-term quality of life challenges. This research evaluates multiple treatments used in ICU care through a flexible, adaptive platform trial called INCEPT. The trial aims to continuously learn and improve treatment by assessing many interventions simultaneously, involving patients, families, and clinicians to make research more relevant and efficient. INCEPT assesses different treatments such as albumin administration during circulatory failure and various dosing regimens of low-molecular-weight heparin for thromboprophylaxis in ICU patients. Treatments are organized into domains with specific interventions that can be open-label or blinded. The platform trial continuously adds new treatment domains and uses adaptive methods to stop ineffective treatments and adjust randomization based on ongoing results. Participants are adults acutely admitted to the ICU and eligible for at least one treatment domain. They will be randomized to receive different interventions during their ICU stay. Researchers will monitor outcomes including days alive without life support, days alive out of hospital, mortality at 30, 90, and 180 days, cognitive function, and health-related quality of life up to 180 days after randomization. The trial uses rigorous statistical methods and includes extensive stakeholder involvement to guide its progress and improve ICU care over time.

The Intensive Care Platform Trial